1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Overcoming heterogeneity in AML with a novel or-gated HITCAR-1XX platform
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Garcia Angus, A.; Chang, Q.; De Stanchina, E.; Sadelain, M.
    Blood (2022)

    Fulltext@MSK | Save
  • Target densities in malignant and normal cells determine CAR T cell efficacy and off-target hematotoxicity
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; De Stanchina, E.; Fraser, K.; Park, J. H.; Wang, X.; Rivière, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy
    Editorial

    Klebanoff, C. A.; Chandran, S. S.
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Sequencing novel agents in frontline and second-line treatment of Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Genetic ablation of adhesion ligands effectively averts rejection of allogeneic immune cells
    Meeting Abstract

    Hammer, Q.; Perica, K.; Mbofung, R. M.; Van Ooijen, H.; Goodridge, J. P.; Valamehr, B.; Önfelt, B.; Sadelain, M.; Malmberg, K. J.
    European Journal of Immunology (2022)

    Fulltext@MSK | Save
  • PRC2 inactivating mutations amplify cell death in response to DNMT1-targeted therapy through enhanced viral mimicry in malignant peripheral nerve sheath tumor
    Meeting Abstract

    Chi, P.; Patel, A. J.; Warda, S.; Maag, J. L. V.; Misra, R.; Miranda-Román, M. A.; Pachai, M. R.; Lee, C. J.; Li, D.; Wang, N.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save